This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0003319707309656v1 59/5/549    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by de Albuquerque, R. M. Articles by Bouskela, E. Search for Related Content PubMed PubMed Citation Articles by de Albuquerque, R. M. Articles by Bouskela, E. Social Bookmarking                         What's this?

Effects of Cilostazol and Pentoxifylline on Forearm Reactive Hyperemia Response, Lipid Profile, Oxidative Stress, and Inflammatory Markers in Patients With Intermittent Claudication

State University of Rio de Janeiro

^* To whom correspondence should be addressed. E-mail: eliete_bouskela{at}yahoo.com.br.

	Abstract

Peripheral arterial disease may lead to lower limb claudication and increased risk of systemic vascular dysfunction. In this article, the authors have investigated the peripheral vascular dysfunction evaluating forearm blood flow using venous occlusion plethysmography, lipid profile, and C-reactive protein in 60 patients with moderate intermittent claudication treated during 20 weeks with placebo (n = 16), cilostazol (200 mg/d; n = 17), or pentoxifylline (1200 mg/d; n = 15) in a randomized double-blinded clinical trial, taking into account smoking. Forearm blood flow after reactive hyperemia response (FBF_h) or oral nitroglycerine spray to evaluate endothelial-dependent and endothelial-independent vasodilation, respectively, pain-free and maximal walking distance, levels of C-reactive protein, triglycerides, cholesterol, low-density lipoprotein, and high-density lipoprotein–cholesterol in plasma were determined. The results showed that there was an improvement in the high-density lipoprotein–cholesterol, pain-free and maximal walking distance, and FBF_h independent of treatment in nonsmoking patients. Cilostazol increased high-density lipoprotein–cholesterol level, maximal walking distance, and FBF_h, whereas pentoxifylline reduced C-reactive protein level and increased maximal walking distance in total and nonsmoking groups. No treatment was effective in smokers

First published on April 2, 2008, doi:10.1177/0003319707309656

Angiology 2008;59:549.

A more recent version of this article appeared on October 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?